AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a ...

AbbVie has agreed to buy Aliada Therapeutics, a biotechnology company backed by Johnson & Johnson, for $1.4 billion in cash ...

RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...

Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize ...

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

Aldeyra Therapeutics (ALDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas ...

AbbVie cuts 2024 profit forecast citing R&D expenses Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $ ...